This may be attributable to the selection of newer drug generations with a lower risk of hypoglycemia, albeit higher costs, including dipeptidyl peptidase-4 inhibitors, sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 agonists. This evidence concerns the gene DPP4 and Hypoglycemia.